Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotaxel + Trastuzumab in HER2+ Metastatic Breast Cancer
NCT00387907Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2006
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of larotaxel in breast cancer, sponsored by Sanofi. Primary endpoint: Tumor response measured. Started Oct 2006; status: completed.
02
Drugs
larotaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00387907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387907.